Panacea Life Sciences Holdings（PLSH）株式概要パナシア・ライフサイエンス・ホールディングスは、持株会社として、ヘンプ由来のカンナビノイド、機能性キノコ、クラトム、植物由来成分、栄養補助食品の開発、製造、研究、生産、販売を消費者とペット向けに行っている。 詳細PLSH ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( $2M )US市場と比較して、過去 3 か月間の株価の変動が非常に大きい最新の財務報告は1年以上前のものである すべてのリスクチェックを見るPLSH Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0367.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-8m6m2016201920222025202620282031Revenue US$2.8mEarnings US$405.8kAdvancedSet Fair ValueView all narrativesPanacea Life Sciences Holdings, Inc. 競合他社Universe PharmaceuticalsSymbol: NasdaqCM:UPCMarket cap: US$1.6mClearmind MedicineSymbol: NasdaqCM:CMNDMarket cap: US$2.3mSciSparcSymbol: NasdaqCM:SPRCMarket cap: US$2.4mPRF TechnologiesSymbol: NasdaqCM:PRFXMarket cap: US$1.3m価格と性能株価の高値、安値、推移の概要Panacea Life Sciences Holdings過去の株価現在の株価US$0.0352週高値US$0.2052週安値US$0.021ベータ01ヶ月の変化0%3ヶ月変化-26.83%1年変化-18.03%3年間の変化-92.68%5年間の変化n/aIPOからの変化-99.21%最新ニュースお知らせ • Jul 16Panacea Life Sciences Holdings, Inc. Files Form 15Panacea Life Sciences Holdings, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share.お知らせ • Jun 13Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 30,000,000 Price\Range: $0.05 to $0.2 Discount Per Security: $0お知らせ • Oct 07Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023. Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc. on October 5, 2023.お知らせ • Aug 17Panacea Life Sciences Holdings, Inc. announced delayed 10-Q filingOn 08/15/2023, Panacea Life Sciences Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 03Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million on August 2, 2023. The consideration includes $2 million in cash, $3 million worth of Panacea Stock and additional earn-out components consisting of $15 million of Panacea Stock. The transaction is subject to Panacea’s satisfactory completion of due diligence of SSH and Halucenex, receipt of applicable corporate approvals of the transaction by the board of directors and shareholders, the execution of the definitive agreement and any ancillary agreements, the receipt of any regulatory approvals and third-party consents, financing (debt or equity) arrangements for Panacea’s $2 million cash payment and projected cash flow deficits from the transaction, on terms satisfactory to Panacea, certain key management personnel and employees entering into consultancy and restrictive covenant agreements with Panacea on terms agreed to with Panacea, confirmation that SSH and Halucenex own their respective intellectual property or licenses and have all required approval for all business operations and ownership including legal and regulatory approvals, by all regulatory agencies, there being no material adverse change in the business, results of operations, prospects, condition (financial or otherwise) or assets of SSH and Halucenex. Paradox Capital Partners, LLC acted as advisor to Panacea.お知らせ • Jul 12Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp on July 3, 2023. The purchase price for the acquisition consists of no cash and the agreement to issue approximately 85,000 shares of a new class of convertible preferred stock, which is convertible into approximately 8.5 million shares of common stock to Nitro Kava & Kratom. The acquisition includes eight retail locations in the Tampa, Florida area, offering Kava, Kratom, VAPE and CBD products and beverages operating as Nitro Kava & Kratom, including inventory, equipment and recipes, distribution facilities and a warehouse located in Largo, Florida. Nitro Kava & Kratom generated $2.9 million of annual revenues (unaudited) for the fiscal year ended December 31, 2022. Closing of the acquisition is subject to satisfaction of customary terms and conditions for a transaction of this kind, including delivery by sellers of audited financial statements for the prior two completed fiscal years for the acquisition. The transaction is subject to N7 Enterprises shareholders.最新情報をもっと見るRecent updatesお知らせ • Jul 16Panacea Life Sciences Holdings, Inc. Files Form 15Panacea Life Sciences Holdings, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share.お知らせ • Jun 13Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 30,000,000 Price\Range: $0.05 to $0.2 Discount Per Security: $0お知らせ • Oct 07Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023. Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc. on October 5, 2023.お知らせ • Aug 17Panacea Life Sciences Holdings, Inc. announced delayed 10-Q filingOn 08/15/2023, Panacea Life Sciences Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 03Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million on August 2, 2023. The consideration includes $2 million in cash, $3 million worth of Panacea Stock and additional earn-out components consisting of $15 million of Panacea Stock. The transaction is subject to Panacea’s satisfactory completion of due diligence of SSH and Halucenex, receipt of applicable corporate approvals of the transaction by the board of directors and shareholders, the execution of the definitive agreement and any ancillary agreements, the receipt of any regulatory approvals and third-party consents, financing (debt or equity) arrangements for Panacea’s $2 million cash payment and projected cash flow deficits from the transaction, on terms satisfactory to Panacea, certain key management personnel and employees entering into consultancy and restrictive covenant agreements with Panacea on terms agreed to with Panacea, confirmation that SSH and Halucenex own their respective intellectual property or licenses and have all required approval for all business operations and ownership including legal and regulatory approvals, by all regulatory agencies, there being no material adverse change in the business, results of operations, prospects, condition (financial or otherwise) or assets of SSH and Halucenex. Paradox Capital Partners, LLC acted as advisor to Panacea.お知らせ • Jul 12Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp on July 3, 2023. The purchase price for the acquisition consists of no cash and the agreement to issue approximately 85,000 shares of a new class of convertible preferred stock, which is convertible into approximately 8.5 million shares of common stock to Nitro Kava & Kratom. The acquisition includes eight retail locations in the Tampa, Florida area, offering Kava, Kratom, VAPE and CBD products and beverages operating as Nitro Kava & Kratom, including inventory, equipment and recipes, distribution facilities and a warehouse located in Largo, Florida. Nitro Kava & Kratom generated $2.9 million of annual revenues (unaudited) for the fiscal year ended December 31, 2022. Closing of the acquisition is subject to satisfaction of customary terms and conditions for a transaction of this kind, including delivery by sellers of audited financial statements for the prior two completed fiscal years for the acquisition. The transaction is subject to N7 Enterprises shareholders.お知らせ • Jan 24Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023.お知らせ • Jul 24Panacea Life Sciences Holdings, Inc. Announces Resignation of Janice Nerger to Its Board of DirectorsPanacea Life Sciences Holdings, Inc. announced that on July 21, 2022, Dr. Janice Nerger resigned as a member of the Board of Directors, effective immediately. Dr. Nerger has accepted the position of interim provost at Colorado State University and has decided to focus on her new position.お知らせ • Jul 15Panacea Life Sciences Announces Launch of CBDA Oil Drops as Potential Complementary Treatment for Long COVIDPanacea Life Sciences Holdings, Inc. announced the addition of CBDA Oil Drops, which is thought to provide potential advantages as a preventative agent against SARS-CoV-2 as well as the effects of Long COVID. In January 2022, the results of a study led by Oregon State University researcher Richard van Breemen were published in the Journal of Natural Products and concluded that CBDA and CBGA can bind to the SARS-CoV-2 spike protein, blocking the virus's ability to infect people. Much more research is necessary to make definitive claims, but as a compliment to vaccines, CBD and CBDA may provide effective prevention and treatment of SARS-CoV-2. Panacea's CBDA Oil Drops tincture, which contains 50mg of CBDA per serving as well as immunity boosting Zinc and Vitamin D, remains one of few products of its kind to be available on the market.お知らせ • Aug 18Exactus, Inc. announced delayed 10-Q filingOn 08/17/2021, Exactus, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.株主還元PLSHUS PharmaceuticalsUS 市場7D4.5%5.0%1.1%1Y-18.0%44.3%28.7%株主還元を見る業界別リターン: PLSH過去 1 年間で44.3 % の収益を上げたUS Pharmaceuticals業界を下回りました。リターン対市場: PLSHは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is PLSH's price volatile compared to industry and market?PLSH volatilityPLSH Average Weekly Movement22.6%Pharmaceuticals Industry Average Movement10.1%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: PLSHの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のPLSHのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2008n/aLeslie Buttorffwww.panacealife.comパナシア・ライフサイエンス・ホールディングスは、持株会社として、ヘンプ由来のカンナビノイド、機能性キノコ、クラトム、植物由来成分、栄養補助食品の開発、製造、研究、生産、販売を消費者とペット向けに行っている。また、他のヘンプ企業へのホワイトラベル販売や製造委託販売、原料販売、委託販売も行っている。さらに、PANA Health、PANA Beauty、PANA Pet、PANA Sport、PANA Pure、PANA Lifeのブランド名で自然療法を提供している。同社は2008年に法人化され、コロラド州グリーンウッドビレッジに本社を置いている。もっと見るPanacea Life Sciences Holdings, Inc. 基礎のまとめPanacea Life Sciences Holdings の収益と売上を時価総額と比較するとどうか。PLSH 基礎統計学時価総額US$1.78m収益（TTM）-US$7.67m売上高(TTM)US$2.76m0.0xP/Sレシオ0.0xPER（株価収益率PLSH は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PLSH 損益計算書（TTM）収益US$2.76m売上原価US$6.63m売上総利益-US$3.87mその他の費用US$3.80m収益-US$7.67m直近の収益報告Mar 31, 2024次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%PLSH の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 17:58終値2026/05/22 00:00収益2024/03/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Panacea Life Sciences Holdings, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 16Panacea Life Sciences Holdings, Inc. Files Form 15Panacea Life Sciences Holdings, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share.
お知らせ • Jun 13Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 30,000,000 Price\Range: $0.05 to $0.2 Discount Per Security: $0
お知らせ • Oct 07Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023. Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc. on October 5, 2023.
お知らせ • Aug 17Panacea Life Sciences Holdings, Inc. announced delayed 10-Q filingOn 08/15/2023, Panacea Life Sciences Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 03Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million on August 2, 2023. The consideration includes $2 million in cash, $3 million worth of Panacea Stock and additional earn-out components consisting of $15 million of Panacea Stock. The transaction is subject to Panacea’s satisfactory completion of due diligence of SSH and Halucenex, receipt of applicable corporate approvals of the transaction by the board of directors and shareholders, the execution of the definitive agreement and any ancillary agreements, the receipt of any regulatory approvals and third-party consents, financing (debt or equity) arrangements for Panacea’s $2 million cash payment and projected cash flow deficits from the transaction, on terms satisfactory to Panacea, certain key management personnel and employees entering into consultancy and restrictive covenant agreements with Panacea on terms agreed to with Panacea, confirmation that SSH and Halucenex own their respective intellectual property or licenses and have all required approval for all business operations and ownership including legal and regulatory approvals, by all regulatory agencies, there being no material adverse change in the business, results of operations, prospects, condition (financial or otherwise) or assets of SSH and Halucenex. Paradox Capital Partners, LLC acted as advisor to Panacea.
お知らせ • Jul 12Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp on July 3, 2023. The purchase price for the acquisition consists of no cash and the agreement to issue approximately 85,000 shares of a new class of convertible preferred stock, which is convertible into approximately 8.5 million shares of common stock to Nitro Kava & Kratom. The acquisition includes eight retail locations in the Tampa, Florida area, offering Kava, Kratom, VAPE and CBD products and beverages operating as Nitro Kava & Kratom, including inventory, equipment and recipes, distribution facilities and a warehouse located in Largo, Florida. Nitro Kava & Kratom generated $2.9 million of annual revenues (unaudited) for the fiscal year ended December 31, 2022. Closing of the acquisition is subject to satisfaction of customary terms and conditions for a transaction of this kind, including delivery by sellers of audited financial statements for the prior two completed fiscal years for the acquisition. The transaction is subject to N7 Enterprises shareholders.
お知らせ • Jul 16Panacea Life Sciences Holdings, Inc. Files Form 15Panacea Life Sciences Holdings, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share.
お知らせ • Jun 13Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 30,000,000 Price\Range: $0.05 to $0.2 Discount Per Security: $0
お知らせ • Oct 07Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023. Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc. on October 5, 2023.
お知らせ • Aug 17Panacea Life Sciences Holdings, Inc. announced delayed 10-Q filingOn 08/15/2023, Panacea Life Sciences Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 03Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million on August 2, 2023. The consideration includes $2 million in cash, $3 million worth of Panacea Stock and additional earn-out components consisting of $15 million of Panacea Stock. The transaction is subject to Panacea’s satisfactory completion of due diligence of SSH and Halucenex, receipt of applicable corporate approvals of the transaction by the board of directors and shareholders, the execution of the definitive agreement and any ancillary agreements, the receipt of any regulatory approvals and third-party consents, financing (debt or equity) arrangements for Panacea’s $2 million cash payment and projected cash flow deficits from the transaction, on terms satisfactory to Panacea, certain key management personnel and employees entering into consultancy and restrictive covenant agreements with Panacea on terms agreed to with Panacea, confirmation that SSH and Halucenex own their respective intellectual property or licenses and have all required approval for all business operations and ownership including legal and regulatory approvals, by all regulatory agencies, there being no material adverse change in the business, results of operations, prospects, condition (financial or otherwise) or assets of SSH and Halucenex. Paradox Capital Partners, LLC acted as advisor to Panacea.
お知らせ • Jul 12Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp on July 3, 2023. The purchase price for the acquisition consists of no cash and the agreement to issue approximately 85,000 shares of a new class of convertible preferred stock, which is convertible into approximately 8.5 million shares of common stock to Nitro Kava & Kratom. The acquisition includes eight retail locations in the Tampa, Florida area, offering Kava, Kratom, VAPE and CBD products and beverages operating as Nitro Kava & Kratom, including inventory, equipment and recipes, distribution facilities and a warehouse located in Largo, Florida. Nitro Kava & Kratom generated $2.9 million of annual revenues (unaudited) for the fiscal year ended December 31, 2022. Closing of the acquisition is subject to satisfaction of customary terms and conditions for a transaction of this kind, including delivery by sellers of audited financial statements for the prior two completed fiscal years for the acquisition. The transaction is subject to N7 Enterprises shareholders.
お知らせ • Jan 24Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023.
お知らせ • Jul 24Panacea Life Sciences Holdings, Inc. Announces Resignation of Janice Nerger to Its Board of DirectorsPanacea Life Sciences Holdings, Inc. announced that on July 21, 2022, Dr. Janice Nerger resigned as a member of the Board of Directors, effective immediately. Dr. Nerger has accepted the position of interim provost at Colorado State University and has decided to focus on her new position.
お知らせ • Jul 15Panacea Life Sciences Announces Launch of CBDA Oil Drops as Potential Complementary Treatment for Long COVIDPanacea Life Sciences Holdings, Inc. announced the addition of CBDA Oil Drops, which is thought to provide potential advantages as a preventative agent against SARS-CoV-2 as well as the effects of Long COVID. In January 2022, the results of a study led by Oregon State University researcher Richard van Breemen were published in the Journal of Natural Products and concluded that CBDA and CBGA can bind to the SARS-CoV-2 spike protein, blocking the virus's ability to infect people. Much more research is necessary to make definitive claims, but as a compliment to vaccines, CBD and CBDA may provide effective prevention and treatment of SARS-CoV-2. Panacea's CBDA Oil Drops tincture, which contains 50mg of CBDA per serving as well as immunity boosting Zinc and Vitamin D, remains one of few products of its kind to be available on the market.
お知らせ • Aug 18Exactus, Inc. announced delayed 10-Q filingOn 08/17/2021, Exactus, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
